{"&cites=6021365036904200257&as_sdt=2005&sciodt=0,5&hl=en":[{"title":"Renal cell carcinoma","url":"http://nuf.nu/NoRenCa/EAU-Guidelines-on-Renal-Cell-Carcinoma-2019.pdf","authors":["B Ljungberg","B Ljungberg K Bensalah","B Ljungberg K Bensalah A Bex","B Ljungberg K Bensalah A Bex S Canfield…"],"year":2015,"numCitations":18,"pdf":"http://nuf.nu/NoRenCa/EAU-Guidelines-on-Renal-Cell-Carcinoma-2019.pdf","citationUrl":"http://scholar.google.com/scholar?cites=1511057121375948271&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:7w3wKnJa-BQJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1511057121375948271&hl=en&as_sdt=2005&sciodt=0,5","publication":"nuf.nu","p":1,"exp":1596898399950},{"title":"NCCN Guidelines Insights: Kidney Cancer, Version 2.2020: Featured Updates to the NCCN Guidelines","url":"https://jnccn.org/view/journals/jnccn/17/11/article-p1278.xml?print&print&print&print&print","authors":["RJ Motzer","RJ Motzer E Jonasch","RJ Motzer E Jonasch MD Michaelson…"],"year":2019,"numCitations":16,"citationUrl":"http://scholar.google.com/scholar?cites=7163102182085008325&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:xZsAnXtzaGMJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=7163102182085008325&hl=en&as_sdt=2005&sciodt=0,5","publication":"jnccn.org"},{"title":"The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)","url":"https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0813-8","authors":["BI Rini","BI Rini D Battle","BI Rini D Battle RA Figlin","BI Rini D Battle RA Figlin DJ George…"],"year":2019,"numCitations":11,"pdf":"https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0813-8","citationUrl":"http://scholar.google.com/scholar?cites=1311514664755829682&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:spt8jqNvMxIJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1311514664755829682&hl=en&as_sdt=2005&sciodt=0,5","publication":"jitc.biomedcentral.com"},{"title":"Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214","url":"https://www.sciencedirect.com/science/article/pii/S0302283819308243","authors":["B Escudier","B Escudier RJ Motzer","B Escudier RJ Motzer NM Tannir","B Escudier RJ Motzer NM Tannir C Porta","B Escudier RJ Motzer NM Tannir C Porta Y Tomita…"],"year":2020,"numCitations":5,"pdf":"https://es.ereprints.elsevier.cc/sites/es.ereprints.elsevier.cc/files/filefield_paths/escudier_en.pdf","citationUrl":"http://scholar.google.com/scholar?cites=12666457087747247632&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:EE7njZxLyK8J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=12666457087747247632&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma","url":"https://journals.sagepub.com/doi/abs/10.1177/1758835920907504","authors":["E Rassy","E Rassy R Flippot","E Rassy R Flippot L Albiges"],"year":2020,"numCitations":5,"pdf":"https://journals.sagepub.com/doi/pdf/10.1177/1758835920907504","citationUrl":"http://scholar.google.com/scholar?cites=3335601220070951944&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:CEywCqNvSi4J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=3335601220070951944&hl=en&as_sdt=2005&sciodt=0,5","publication":"journals.sagepub.com"},{"title":"Checkpoint inhibitor immunotherapy in kidney cancer","url":"https://www.nature.com/articles/s41585-020-0282-3","authors":["W Xu","W Xu MB Atkins","W Xu MB Atkins DF McDermott"],"year":2020,"numCitations":4,"citationUrl":"http://scholar.google.com/scholar?cites=7822855233582147380&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:NCf4PmNdkGwJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=7822855233582147380&hl=en&as_sdt=2005&sciodt=0,5","publication":"nature.com"},{"title":"Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma","url":"https://www.sciencedirect.com/science/article/pii/S1558767319302563","authors":["V Di Nunno","V Di Nunno V Mollica","V Di Nunno V Mollica R Schiavina","V Di Nunno V Mollica R Schiavina E Nobili…"],"year":2020,"numCitations":2,"citationUrl":"http://scholar.google.com/scholar?cites=4900194573288549805&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:rS0phwD9AEQJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=4900194573288549805&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Therapeutic monoclonal antibodies targeting immune checkpoints for the treatment of solid tumors","url":"https://www.mdpi.com/2073-4468/8/4/51","authors":["N Gravbrot","N Gravbrot K Gilbert"],"year":2019,"numCitations":3,"pdf":"https://www.mdpi.com/2073-4468/8/4/51/pdf","citationUrl":"http://scholar.google.com/scholar?cites=16717294110211946602&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:arjp1GvC_-cJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16717294110211946602&hl=en&as_sdt=2005&sciodt=0,5","publication":"mdpi.com"},{"title":"Updated efficacy results from the JAVELIN renal 101 trial: First-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","url":"https://www.sciencedirect.com/science/article/pii/S092375342039308X","authors":["TK Choueiri","TK Choueiri RJ Motzer","TK Choueiri RJ Motzer BI Rini","TK Choueiri RJ Motzer BI Rini J Haanen…"],"year":2020,"numCitations":2,"pdf":"https://www.annalsofoncology.org/article/S0923-7534(20)39308-X/fulltext","citationUrl":"http://scholar.google.com/scholar?cites=12933266032743790557&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:3bdR8-4wfLMJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=12933266032743790557&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Outcomes Associated with First-Line anti-PD-1/PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta …","url":"https://www.mdpi.com/2072-6694/12/2/408","authors":["C Buonerba","C Buonerba P Dolce","C Buonerba P Dolce S Iaccarino","C Buonerba P Dolce S Iaccarino L Scafuri","C Buonerba P Dolce S Iaccarino L Scafuri A Verde…"],"year":2020,"numCitations":1,"pdf":"https://www.mdpi.com/2072-6694/12/2/408/pdf","citationUrl":"http://scholar.google.com/scholar?cites=4488109978461087725&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:7ScPEz_4SD4J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=4488109978461087725&hl=en&as_sdt=2005&sciodt=0,5","publication":"mdpi.com"}]}